[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-migraine-headache\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-migraine-headache":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,51,79,106,133,160,183,203,225,250,282,305,334,357,386,411,443,466],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100641202","embrace-obs-single-site-observational-registry-of-patient-reported-outcomes-following-mma-embolization-for-migraine-100641202",false,"NCT07652034","EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine","Enduring Migraine Benefit From Responsive Artery Coil Embolization - Observational (EMBRACE-OBS): A Single-Site Registry of Patient-Reported Outcomes Following Routine Clinical Care for Migraine","EMBRACE-OBS","Inclusion Criteria:\n\n* Adults aged 18 to 64 years\n* Diagnosis of migraine\n* Have undergone or plan to undergo middle meningeal artery (MMA) embolization as part of routine clinical care, independent of study participation\n* Able and willing to provide informed consent\n* Able to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments\n\nExclusion Criteria:\n\n* Age under 18 years\n* Pregnancy at the time of enrollment\n* Inability to provide informed consent\n* Inability to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments\n* Insufficient clinical or patient-reported outcome data for the planned analyses","ALL","18 Years","64 Years",{"count":21,"type":22},50,"ESTIMATED","12 Months","OBSERVATIONAL","EMBRACE-OBS is the first phase of the EMBRACE research program. This single-site observational registry accesses and analyzes patient-reported outcome data already collected through routine clinical care from adults with migraine who have undergone or plan to undergo middle meningeal artery (MMA) embolization. The study describes changes in headache frequency, headache severity, medication use, migraine-related disability, quality of life, and reported adverse events over time without influencing clinical care.",[27,28,29],"Migraine Disorders","Chronic Migraine Headache","Migraine",[31,32,29,33,34,35,36,37,15],"Middle Meningeal Artery Embolization","MMA Embolization","Headache","Patient-Reported Outcomes","HIT-6","Observational Registry","Neurointervention","NOT_YET_RECRUITING","2026-06-16",{"date":41,"type":42},"2026-06-18","ACTUAL",{"date":44,"type":22},"2026-07-01",{"date":46,"type":22},"2028-06-01",{"name":48,"class":49},"Cortex Neurovascular","INDUSTRY",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100631429","ultrasound-guided-infratemporal-sphenopalatine-ganglion-supravoltage-versus-standard-voltage-pulsed-radiofrequency-for-pain-alleviation-in-chronic-refractory-migraine-100631429","NCT07500558","Ultrasound Guided Infratemporal Sphenopalatine Ganglion Supravoltage Versus Standard Voltage Pulsed Radiofrequency for Pain Alleviation in Chronic Refractory Migraine.","Ultrasound Guided Sphenopalatine Ganglion Supravoltage Versus Standard Voltage Pulsed Radiofrequency for Pain Alleviation in Chronic Refractory Migraine. Randomized Double Blind Study","Inclusion Criteria:\n\n* Diagnosis of chronic migraine according to International Classification of Headache Disorders criteria (≥15 headache days\u002Fmonth for \\>3 months, including ≥8 migraine days\u002Fmonth) documented by Completion of 4-week prospective baseline headache diary immediately preceding randomization\n\n  * Failure of ≥2 classes of preventive pharmacological migraine medications (e.g., beta-blockers, antiepileptics, antidepressants...) to get clinically meaningful response ( defined as ≥50% reduction in monthly migraine days), at standard therapeutic doses (Beta-blockers (e.g., propranolol ≥160 mg\u002Fday, metoprolol ≥100 mg\u002Fday, Antiepileptics (e.g., topiramate ≥100 mg\u002Fday, valproate ≥500 mg\u002Fday, Tricyclic antidepressants (e.g., amitriptyline ≥50 mg\u002Fday, SNRIs (e.g., venlafaxine ≥150 mg\u002Fday ) for at least 8 weeks or ≥12 weeks in case of CGRP ).\n  * Stable preventive migraine therapy for at least 4 weeks prior to enrollment.\n  * MIDAS score ≥11 indicating moderate to severe disability.\n  * Ability and willingness to maintain a daily headache diary throughout the study period.\n  * Ability to provide written informed consent. Positive response (≥50% pain reduction within 30-60 minutes) to diagnostic INFRATEMPORAL sphenopalatine ganglion block using 2% lidocaine (2 mL) infrazygomatic approach\n\nExclusion Criteria:\n\n* Medication Overuse Headache per ICHD-3: Simple analgesics (acetaminophen, NSAIDs, non-opioid analgesics) used on ≥15 days per month for \\>3 months, OR Triptans, ergot derivatives, opioids, or combination analgesics used on ≥10 days per month for \\>3 months.\n* Any secondary headache disorder ( cluster headache, hemiplegic migraine, migraine with brainstem aura (distinct pathophysiology); chronic tension-type headache \\>10 days\u002Fmonth.\n* Any prior SPG block, PRF, radiofrequency thermocoagulation, chemical neurolysis, or neurostimulation of SPG\u002Ftrigeminal system within 6 month.\n* No prior occipital or supra-orbital nerve radiofrequency, cryotherapy, or chemical neurolysis within 3 months\n* Use of botulinum toxin (Botox) within 3 months or CGRP monoclonal antibodies within 3 months prior to enrollment.\n* Active psychosis, bipolar disorder (current manic\u002Fdepressive episode), severe depression with suicidal ideation, dementia, or substance use disorder (DSM-5 criteria) within 12 months; PHQ-9 ≥20 or cognitive impairment affecting reporting reliability.\n* Cardiac pacemaker, ICD, neurostimulator, or cochlear implant; or ECT.\n* Chronic uncontroled hypertension ; history of stroke, intracranial aneurysm, or high risk for cardiovascular events.\n* Pregnancy or lactation, Initiation, discontinuation, or modification of hormonal contraceptive therapy within 3 months prior to enrollment.\n\nCoagulopathy (platelets \\\u003C100,000 or INR \\>1.5) or ongoing anticoagulation not safely withheld.\n\n-Patient refusal.","20 Years","70 Years",{"count":61,"type":22},100,"INTERVENTIONAL",[64],"NA","* PRF performed on the sphenopalatine ganglion level under ultrasound guidance.\n* Standard voltage PRF parameters: 45 V, 5 Hz frequency, 5 ms pulse width, 360 seconds duration, electrode temperature ≤42°C.\n* Supravoltage PRF parameters: Higher voltage than standard (e.g., 60-70 V), with same frequency, pulse width, and duration, maintaining temperature ≤42°C to avoid nerve damage.",[67],"Chronic Migraine, Headache","RECRUITING","2026-06-13",{"date":39,"type":42},{"date":72,"type":42},"2026-03-31",{"date":74,"type":22},"2027-04-02",{"name":76,"class":77},"Minia University","OTHER",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":102,"leadSponsor":104,"locationsCount":50},"100638752","the-neuroanatomical-and-psychological-correlates-of-suggestibility-in-patients-with-non-responsive-chronic-migraine-100638752","NCT07617441","The Neuroanatomical and Psychological Correlates of Suggestibility in Patients With Non-Responsive Chronic Migraine","SIGMA","Inclusion Criteria for Non-Responsive Chronic Migraine subjects:\n\n* adults aged ≥ 18 years and ≤ 75 years;\n* diagnosis of non-responsive chronic migraine (NRCM) according to ICHD-3 beta criteria;\n* presence of at least 8 migraine days per month associated with disability (MIDAS ≥ 11), and insufficient response after 6 weeks or inability to tolerate at least three previously prescribed migraine preventive agents, i.e., resistance to standard therapy for at least 6 weeks;\n* signed informed consent.\n\nInclusion Criteria for healthy subjects are:\n\n* adults aged ≥ 18 years and not older than 75 years;\n* absence of a diagnosis of NRCM according to ICHD3beta or other relevant -neurological disorders as assessed during the medical history taken at the headache center;\n* signed informed consent.\n\nExclusion Criteria:\n\n* older than 75 years;\n* children\n* pregnant or breastfeeding women;\n* history of alcohol or substance abuse;\n* affected by concomitant neurological, cardiovascular, or cerebrovascular diseases;\n* liver disease or kidney disease;\n* psychiatric disorders (psychosis, major depression, bipolar disorder).\n* diagnosis or history of migraine (for healthy subjects).",true,"75 Years",{"count":89,"type":22},200,"Chronic migraine is a disabling neurovascular disorder and one of the leading causes of years lived with disability worldwide. Population-based studies report a worrying level of resistance to currently available treatments in clinical practice. For this reason, the clinical and scientific community is increasingly investigating new therapeutic approaches aimed at reducing the burden of symptoms and improving patients' quality of life.\n\nAmong the alternative therapeutic approaches explored in migraine research, the placebo effect has emerged as a potentially important mechanism. However, the duration and intensity of its beneficial effects on migraine symptoms are still poorly understood. In particular, there is a need to identify biological and clinical markers that may predict which patients are more likely to benefit from placebo-related mechanisms.\n\nOne of the most promising factors is suggestibility, namely the tendency of an individual to respond to suggestions, expectations, or contextual influences. It is possible that patients with non-responsive chronic migraine may show different levels of suggestibility, which could influence the effectiveness of placebo-related responses.\n\nTo investigate this hypothesis, it is first necessary to better understand the psychobiological characteristics of patients with non-responsive chronic migraine (NRCM). Therefore, the primary aim of this monocentric observational study is to characterize the neurobiological and psychological profile of individuals affected by NRCM through advanced magnetic resonance imaging techniques (connectomics) and a comprehensive battery of psychodiagnostic assessments, including the evaluation of suggestibility.\n\nThe study plans to recruit at least 100 patients with NRCM and 100 healthy control subjects matched for age and sex. By comparing participants with high and low levels of suggestibility, the study aims to identify new neurobiological profiles (bio-phenotypes) associated with these characteristics. These findings may contribute to future research on the placebo effect and help develop more personalized treatment strategies for patients with chronic migraine who do not respond to conventional therapies.",[28],[93,94,95,96,97],"Chronic migraine","Suggestibility","Placebo effect","Connectomics","Biomarkers","2026-05-28",{"date":100,"type":42},"2026-06-01",{"date":44,"type":22},{"date":103,"type":22},"2029-05",{"name":105,"class":77},"Istituto per la Ricerca e l'Innovazione Biomedica",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":62,"phases":115,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":78},"100598439","new-methods-for-evaluating-preventive-migraine-treatment-100598439","NCT07071506","New Methods for Evaluating Preventive Migraine Treatment","Inclusion Criteria:\n\n1. Adults (18-65 years)\n2. ≥ 1-year history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria\n3. Known chronic migraine (headache occurring ≥ 15 days per month for \\> 3 months, which on at least 8 days per month has the features of migraine headache) diagnosed before age 65\n4. Eligibility for preventive migraine treatment\n5. Ability to speak and read Danish\n\nExclusion Criteria:\n\n1. Use of onabotulinumtoxinA as preventive migraine treatment during the 4 months before inclusion\n2. Use of other preventive migraine treatment except CGRP antagonists (However, participants are allowed to be on two stable preventive medication (antidepressant, calcium channel blockers, beta blockers or antiepileptic)- 2 months prior to inclusion until end of study), devices for migraine prevention such as transcranial magnetic stimulation and use of nerve blocks 3 months prior to inclusion\n3. Use of opioid or barbiturate medications in the last four weeks before inclusion\n4. Secondary headache disorders including medication overuse headache\n5. Severe psychiatric, vascular disease, or known liver disease\n6. Alcohol abuse or substance abuse\n7. Current or planned pregnancy and lactation","65 Years",{"count":114,"type":22},60,[64],"The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, balanced placebo design, patients with chronic migraine will receive four treatment conditions in a randomized order.",[29,118,119,67],"Migraine With or Without Aura","Headache Disorders",[33,93,121,122,123],"Balanced placebo design","Treatment effects","Adverse events","2026-05-18",{"date":126,"type":42},"2026-05-19",{"date":128,"type":42},"2025-06-19",{"date":130,"type":22},"2028-09",{"name":132,"class":77},"University of Aarhus",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":62,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":50},"100610086","bilateral-embolization-of-the-middle-meningeal-arteries-for-refractory-chronic-migraine-100610086","NCT07223008","Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine","A Pilot Study of Safety and Feasibility of Bilateral Middle Meningeal Artery Embolization (bMMAE) in Patients With Refractory Chronic Migraine Headache: The MMAE-MIGRAINE Trial","MMAE-Migraine","Inclusion criteria:\n\n* Age 18\\\u003Cx\\\u003C80\n* Meets ICHD3 criteria for chronic migraine, (ICHD3, 1.3; with inclusion of ICHD3 1.1 and 1.2.1 only), with first migraine before age 50 (in concordance with previously published trials in migraine therapy36,39) . Patients must experience bilateral migraine symptoms.\n* Satisfy criteria for refractory chronic migraine defined as failure of, inadequate response to, or inability to tolerate migraine preventatives in at least 2 classes. Migraine preventatives include beta-blockers, calcium channel blockers, anti-convulsants (valproic acid, topiramate), anti-depressants (venlafaxine, amitriptyline), CGRP monoclonal antibodies, botulinum toxin injections. Chronic migraines must have persisted for at least 12 months prior to enrollment and at least 6 months after failing 2 classes of medication.\n* Has not used opiates or barbiturates as acute (rescue) therapy for migraine headache. Opiate or barbiturate use for reasons other than migraine is allowed. Other classes of acute migraine medications are acceptable. Acute (rescue, abortive) medications for migraines include acetaminophen, NSAIDs (ibuprofen, naproxen), gepants, triptans, anti-emetics (anti-nausea medications).\n* Exclusion of secondary headache disorder which may cause migraines\u002Fsymptoms, including MRI\u002FMRA (performed as routine care showing no underlying lesion that may be causing headaches, within 3 years of screening).\n* At least one migraine free day during the last month per headache diary.\n* Minimum MIDAS score of 21 (reflecting severely disabling migraine, in concordance with ongoing MMA lidocaine infusion trial44).\n* Able to read\u002Fwrite in English. Patients who are not English language users will not be enrolled as the study assessments are only validated in English.\n* Able to sign informed consent for themselves.\n* Able to complete study requirements\u002Ffollow-up as outlined in study plan section 3.6.\n\nExclusion criteria:\n\n* History of cranial or cervical vascular interventions or surgery, including craniotomy\u002Fcraniectomy, shunt placement, stereoelectroencephalography, and carotid endarterectomy.\n* A history of opiate or barbiturate use for the treatment of chronic migraine within one year.\n* Current intracranial lesions as determined by routine care MRI for exclusion of secondary headache disorders.\n* History of cranial radiation treatment.\n* Patients with additional diagnoses under ICHD3 (such as hemiplegic migraine, basilar migraine, new daily persistent headache, or cluster headache) are ineligible\n* Significant liver function impairment or serum creatinine \\> 2.0 mg\u002FdL. Patients with elevated creatinine levels who are on dialysis may be eligible.\n* History of systemic malignancy or auto-immune inflammatory disorders (such as multiple sclerosis, rheumatoid arthritis, autoimmune diseases).\n* History of life-threatening allergy to radiographic contrast. Patients with this allergy may be eligible if it can be managed medically.\n* Enrollment in another migraine study which could confound this study's endpoints, including undergoing any intervention or receiving an experimental drug under investigation for migraine therapy.\n* Additional medical or social concerns which could confound this study's endpoints or otherwise create undue risk or interfere with the participant's ability to complete the study, as assessed by the PI.\n* As this study is open only to patients with chronic migraine, which is refractory to treatment, patients who have previously been diagnosed with chronic migraine but now experience episodic migraine due to effective therapy are not eligible.\n* Patients with additional diagnoses under ICHD3 (such as hemiplegic migraine, basilar migraine, new daily persistent headache, or cluster headache) are ineligible.","80 Years",{"count":143,"type":22},13,[64],"This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study.\n\nParticipants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.",[29,28,147],"Refractory Migraine",[149,150],"embolization","middle meningeal artery","2026-04-28",{"date":153,"type":42},"2026-05-04",{"date":155,"type":42},"2026-04-24",{"date":157,"type":22},"2028-04",{"name":159,"class":77},"Johns Hopkins University",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":62,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":50},"100634133","botulinum-toxin-andor-greater-occipital-nerve-block-for-patients-with-chronic-migraine-100634133","NCT07535723","Botulinum Toxin and\u002For Greater Occipital Nerve Block for Patients With Chronic Migraine","Inclusion Criteria:\n\n* Diagnosis of chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3): headache occurring on ≥15 days per month for more than three months, with at least 8 days per month exhibiting migraine features. (International Headache Society, 2013)\n* Age \\> 18 years\n* Stable preventive migraine regimen for at least two months prior to recruitment\n\nExclusion Criteria:\n\n* Co-morbid other\n* Prior treatment with BoNT-A or GONB for headache within the previous 3 months.\n* Known hypersensitivity to BoNT-A or local anesthetics.\n* Cervical anatomical abnormalities that hinder proper localization of injection sites or compromise the safety of the procedure\n* Neuromuscular junction disorders (e.g., myasthenia gravis).\n* Coagulation disorders or anticoagulant therapy that contraindicates nerve block.\n* Significant psychiatric comorbidity that would impair proper pre and post treatment assessment.\n* Pregnancy.",{"count":167,"type":22},90,[64],"Chronic migraine is a debilitating neurological disorder that significantly affects patients' daily functioning, mental health, and quality of life. Management typically includes acute and preventive treatments, but effectiveness can be limited due to medication overuse or delayed onset of action. OnabotulinumtoxinA injections provide proven long-term preventive benefits, while Greater Occipital Nerve (GON) block offers rapid but short-term relief. Although both treatments are used individually, evidence on the combined effect is limited. This randomized controlled trial aims to evaluate the efficacy and safety of combining OnabotulinumtoxinA injections with GON block, assessing improvements in headache frequency, severity, and patient quality of life compared to single therapy.",[28,171,172,173],"OnabotulinumtoxinA","Greater Occipital Nerve Block","Combination Therapy","2026-04-15",{"date":176,"type":42},"2026-04-17",{"date":178,"type":22},"2026-04",{"date":180,"type":22},"2026-12",{"name":182,"class":77},"Beni-Suef University",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":190,"targetDuration":4,"studyType":62,"phases":192,"briefSummary":188,"conditions":193,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100632325","comparison-between-greater-occipital-nerve-block-and-pulsed-radiofrequency-in-the-management-of-chronic-migraine-100632325","NCT07512219","Comparison Between Greater Occipital Nerve Block and Pulsed Radiofrequency in the Management of Chronic Migraine","Comparative Study of Greater Occipital Nerve Block and Pulsed Radiofrequency in the Management of Chronic Migraine : Clinical Outcomes and Neurophysiological Correlates A Prospective Randomized Study","Inclusion Criteria:\n\n* patient with Diagnosis of chronic migraine for \\> 3 months.\n* migraine days ≥ 15 days\u002Fmonth.\n* Failure or inadequate response to standard medical treatment.\n\nExclusion Criteria:\n\n* Secondary headache disorders.\n* Coagulopathy or anticoagulant therapy.\n* Infection at injection site.\n* History of cervical spine surgery.\n* Pregnancy or breastfeeding.\n* Previous PRF or occipital nerve surgery within last 3 months",{"count":191,"type":22},70,[64],[67],"2026-03-30",{"date":196,"type":42},"2026-04-06",{"date":198,"type":22},"2026-05-01",{"date":200,"type":22},"2027-05-01",{"name":202,"class":77},"Sohag University",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":210,"targetDuration":4,"studyType":62,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":50},"100619626","clinical-study-of-myofascial-trigger-pointsmtrps-injection-in-the-treatment-of-chronic-migraine-100619626","NCT07347067","Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Migraine","Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Musculoskeletal Pain(CMP), Chronic Migraine and Cervicogenic Headache","Inclusion Criteria:\n\n* Diagnosed with migraine by at least two pain specialists or neurologists;\n* Disease duration of at least 3 months;\n* Age between 18 and 65 years;\n* Numerical Rating Scale (NRS) score ≥ 3 despite conservative pharmacological treatment;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* History of allergy to trial medications such as corticosteroids;\n* Alcohol abuse; long-term use of opioids (exceeding 2 weeks or more than 3 days per week for over 1 month); suspected use of sedative or analgesic medications; patients on long-term steroid therapy;\n* Severe neurological disorders, significant hepatic or renal dysfunction, heart failure, coagulation abnormalities, gastric ulcer, diabetes, inflammatory rheumatic diseases, etc.;\n* Inability to use pain assessment scales;\n* Presence of local or systemic infection;\n* Pregnant or lactating patients.",{"count":211,"type":22},1036,[64],"Chronic migraine is a common disease in China, with a high incidence among the elderly, and has a significant impact on patients' quality of life. Currently, both domestic and international studies have confirmed that glucocorticoid injection at myofascial trigger points(MTrPs) can alleviate patients' pain symptoms. MTrPs injection is safe and easy to operate, and can improve the clinical management efficiency of patients with chronic migraine. Therefore, we designed a prospective, randomized controlled, blinded outcome, non-inferiority study to compare the long-term clinical efficacy of glucocorticoid injection at myofascial trigger points and greater occipital nerve block injection in treating chronic migraine. Patients will be randomly divided into two groups and receive either glucocorticoid injection at MTrPs or greater occipital nerve. After treatment, patients will be followed up for 2 years. Their NRS scores, attack frequency, attack duration, HIT-6 scores, Patient Global Impression of Change(PGIC) scale, and adverse reactions will be recorded at 2 weeks, 4 weeks, 8 weeks, 12 weeks, and 24 weeks. If the results indicate that the clinical efficacy of myofascial trigger point injection for chronic migraine is not inferior to that of injection at intra-articular injection, it will provide a safe and simple treatment option that is easy to promote for patients who do not respond to conservative treatment.",[215,28,172],"Myofascial Trigger Points","2026-01-11",{"date":218,"type":42},"2026-01-16",{"date":220,"type":42},"2025-12-01",{"date":222,"type":22},"2027-06-01",{"name":224,"class":77},"Beijing Tiantan Hospital",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":232,"targetDuration":4,"studyType":62,"phases":234,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":248,"locationsCount":4},"100609428","tcds-for-the-treatment-of-chronic-migraine-100609428","NCT07214454","TCDS for the Treatment of Chronic Migraine","An Open Label, Single-site Feasibility Study of Transcranial Direct Current Stimulation (tCDS), Using the Nettle Device, for the Treatment of Chronic Migraine.","Inclusion Criteria:\n\n1. Subjects aged 18-70 years\n2. Fulfil the International Classification of Headache Disorders -3 (ICHD-3) criteria for chronic migraine, diagnosed by a headache specialist, at least 1 year prior to entering the trial\n3. Subject is willing to keep headache medications stable for two weeks prior to entering the study and for the duration of the study.\n4. Access to a smart phone to use the mobile application to control the device and use the Headache Pro app to record headaches. A paper diary may be used instead of the Headache Pro app Id required by individual patients.\n5. Subject is able to provide written informed consent prior to participation in the study\n6. Females of childbearing potential agree to use an effective method of contraception from the time consent is signed until treatment discontinuation. Effective methods of contraception acceptable for this trial are the oral contraceptive pill, patch, implant, injection, ring, intra-uterine system, copper coil, barrier methods, partner vasectomy or abstinence. Participants are considered not of child bearing potential if they are surgically sterile (i.e. they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal\n7. If there is any possibility of pregnancy, females of childbearing potential should have a negative pregnancy test within 7 days of commencing the treatment phase.\n8. Subject must be willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Epilepsy or history of seizures\n2. Current or planned pregnancy during the study timeframe\n3. Active suicidal thoughts\n4. Pre-existing neurological or neuropsychiatric condition\n5. Lesion, tumour or other defect in skull or brain\n6. Implant inside skill, cochlear implant or implanted hearing aid.\n7. Implanted medical device e.g. pacemaker or neurostimulator\n8. Use of other stimulation devices such as spinal cord stimulators, vagal nerve stimulation, auricular nerve stimulator or deep brain stimulation.\n9. Concurrent medication overuse\n10. Use of cranial botulinum toxin injections or CGRP inhibitors in the past 6 months\n11. Current or recent (within three months) participation in another clinical trial.\n12. Planned surgical or significant medical intervention during the study period which may affect the study results, at the discretion of the chief investigator.\n13. Lacking mental capacity to give informed written consent.",{"count":233,"type":22},20,[64],"Migraine affects 1 in 7 people worldwide, but for those suffering from chronic migraine there is a need for safe, effective and well tolerated treatments. The Nettle device is a non-invasive device, which is worn like a headband and delivers electrical stimulation (known as transcranial direct current stimulation or TCDS) to areas of the brain known to be involved in the processing of pain. In this study, 20 patients will be trained on how to use the device and then use it daily at home for 20 minutes for three months. Patients will complete a headache diary and quality of life questionnaires before using the device, during and after. As this is a feasibility study, adherence to completing the diaries and questionnaires will be assessed. Compliance with the treatment paradigm will also be assessed.",[28,237],"Transcranial Direct Current Stimulation",[239,240,241],"chronic migraine treatment","transcranial direct current stimulation","non-invasive neuromodulation","2025-11-26",{"date":244,"type":42},"2025-12-04",{"date":246,"type":22},"2026-02-01",{"date":100,"type":22},{"name":249,"class":77},"University College, London",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":257,"targetDuration":259,"studyType":24,"phases":4,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":281},"100605225","real-world-prospective-study-on-the-use-of-anti-cgrp-drugs-in-migraine-100605225","NCT07159750","Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine","EUREkA","Inclusion Criteria:\n\n* Migraine diagnosis according to ICHD-III.\n* Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.\n* Signature of informed consent.\n\nExclusion Criteria:\n\n* Presence of headache different from migraine.\n* Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.",{"count":258,"type":22},700,"2 Years","The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.",[29,262,67],"Episodic Migraine",[29,264,265,262,266,267,268,269,270,271],"Prevention","Chronic Migraine","galcanezumab","erenumab","fremanezumab","eptinezumab","rimegepant","atogepant","2025-08-29",{"date":274,"type":42},"2025-09-08",{"date":276,"type":42},"2024-01-02",{"date":278,"type":22},"2026-01",{"name":280,"class":77},"Hospital Universitari Vall d'Hebron Research Institute",26,{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":62,"phases":291,"briefSummary":292,"conditions":293,"keywords":294,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":304,"locationsCount":4},"100599683","occipital-nerve-stimulation-in-chronic-migraine-100599683","NCT07087678","Occipital Nerve Stimulation in Chronic Migraine","A Prospective, Randomised, Open Label Feasibility Trial Comparing BurstDR Microdosing Versus Tonic Occipital Nerve Stimulation for Patients With Refractory Chronic Migraine","Inclusion Criteria:\n\nAge ≥ 18 years old and diagnosed with intractable chronic migraine by a headache specialist, as defined by the International Classification of Headache Disorders-3 (ICHD-3).\n\nSubject should have failed to gain benefit from at least 4 classes of oral preventative medications, Botulinum toxin or acupuncture as defined by NHS (National Health Service) England Subject has been diagnosed at least 6 months prior to study enrolment with migraine headache with or without aura according to the ICHD-3 criteria 1.1, 1.2.1, or 1.3.\n\nSubject is able to distinguish migraine attacks from other headaches (e.g. tension type headache, cluster headaches).\n\nSubject agrees to not participate in supplemental or alternative therapy through the Follow Up Period of the study. This includes acupuncture, spinal manipulation, TENS (transcutaneous electrical nerve stimulation), and magnetic fields treatments.\n\nSubject has the ability to read, comprehend, and to reliably record information as required by the Protocol.\n\nSubject is able to provide written informed consent prior to participation in the study.\n\nExclusion Criteria:\n\nSubject's overall health, age and\u002For comorbidities place subject at high risk for complications from surgery and\u002For general anaesthesia.\n\nSubject has clinically significant drug (including opioid) or alcohol abuse as defined by DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision), will likely be unable to refrain from substance abuse throughout the study, has another significant pain problem, substance abuse or active depressive episode that might confound the study assessments in the opinion of the Investigator.\n\nSubject is currently participating or has participated in the last month in another clinical study in which the subject has, is, or will be exposed to, an investigational drug or device, except for sponsor-related studies.\n\nSubject is felt to be at risk of non-compliance (e.g., for completing the diary\u002Fquestionnaires or returning for required follow-up visits) in the Investigator's opinion.\n\nSubject has medication overuse headache which has not been managed (by withdrawal of the causative medication).\n\nSubject is a woman of childbearing potential who is pregnant, nursing, or not using effective contraception.\n\nSubject has an active implantable device such as pacemaker\u002F defibrillator or other neurostimulation device.\n\nSubject has a history of bleeding disorders or coagulopathy or is unable to discontinue anticoagulation, antiplatelet, or GP (glycoprotein) IIb IIIa inhibitor medication in preparation for the implantation procedure.\n\nSubject is not suitable for the study for any reason in the judgment of the Investigator.",{"count":290,"type":22},40,[64],"The goal of this clinical trial is to compare two different types of occipital nerve stimulation (BurstDR (dorsal root) microdosing versus Tonic) in chronic refractory migraine. The main questions it aims to answer is whether BurstDR microdosing is effective in reducing moderate to severe headache days compared to Tonic stimulation (which is currently in use). Additionally, the safety of both types of stimulation will be studied.\n\nParticipants will be asked to keep a headache diary, then have the device implanted and programmed, and keep a subsequent headache diary to see if there is an improvement in their headaches after three moths of stimulation. If they don't respond to treatment, they will be allowed to swap to the other type of stimulation to see if this improves their symptoms.",[67,147],[93,295,296,297],"Occipital nerve stimulation","BurstDR microdosing","Refractory migraine","2025-07-18",{"date":300,"type":42},"2025-07-28",{"date":302,"type":22},"2025-09-01",{"date":46,"type":22},{"name":249,"class":77},{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":313,"targetDuration":4,"studyType":62,"phases":315,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":333},"100596081","phase-3-the-nordic-chronic-migraine-trial-of-cgrp-monoclonal-antibody-and-onabotulinumtoxin-a-dual-therapy-compared-to-cgrp-mabs-monotherapy-100596081","NCT07040813","The Nordic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumtoxin A Dual Therapy Compared to CGRP mAbs Monotherapy","A Randomized Placebo-controlled Double-blind Phase III Trial to Investigate the Reduction of Monthly Migraine Days (MMDs) Over 12 Weeks of Treatment With CGRP mAbs and Onabotulinumtoxin A Intramuscularly Compared With CGRP mAbs and Placebo in Chronic Migraine","NorMig","Inclusion criteria\n\n1. Informed and signed written consent.\n2. Individuals of any sex, 18-70 years at the time of signing the informed consent.\n3. Fulfilling the diagnosis chronic migraine criteria 1.3. according to the International Classification of Headache Disorders version 3 at time of inclusion.\n4. Indications for treatment with CGRP mAbs according to SmPCs.\n5. Indications for treatment with BTA according to SmPC.\n6. No previous use of CGRP inhibitors or BTA.\n7. Women of childbearing potential (WOCBP) can only be included if they use a highly effective contraception method\n\nExclusion criteria:\n\n1. Contraindications, allergy or hypersensitivity reactions to BTA including infection at the injection site.\n2. Contraindications, allergy or hypersensitivity reactions to CGRP mAbs including serious cardiovascular illness such as myocardial infarction, stroke, unstable angina pectoris, revascularization procedures last 12 months.\n3. Concomitant medication overuse headache where drug withdrawal has not been done.\n4. Subject is unable to differentiate migraine from other concomitant headaches.\n5. Participation in a clinical study of a new chemical entity or a prescription medicine within 2 months before study inclusion (Visit 2).\n6. Long-standing continuous headache with no headache free days or periods for a period of time \\>1 years.\n7. Pregnancy, planning to get pregnant, inability to use contraceptives and lactating.\n8. High degree of comorbidity and\u002For frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator.\n9. Alcohol or illicit drug dependence.\n10. Investigators may exclude patients who, for various reasons (for example, severe psychiatric disorders), are considered unlikely to be able to complete the tasks required for participation in the study.\n11. Inability to understand study procedures and to comply with them for the entire length of the study, assessed at the discretion of the investigator.",{"count":314,"type":22},450,[316],"PHASE3","Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and\u002For sensitivity to light and\u002For sound.\n\nChronic migraine, which occurs in 1-2 % of the population is characterized by 15 or more headache days\u002Fmonth for more than 3 months and at least 8 days\u002Fmonth with features of migraine headache.\n\nThe study will evaluate the efficacy of onabotulinumtoxin A when added to CGRP monoclonal antibody therapy in chronic migraine prevention. Adverse events and change in disease activity will be monitored.\n\nOnabotulinumtoxin A and CGRP monoclonal antibody therapy are investigational drugs developed to prevent chronic migraine. Approximately 450 patients will be included from sites in Norway.\n\nAll participants will receive CGRP monoclonal antibody therapy. Additionally, the participants will be randomized to receive onabotulinumtoxin A or placebo injections.\n\nTotal study duration is 20 weeks including 3 on site visits and 3 telephone visits. After an inclusion visit the participants are registering data in an electronic headache diary using the application Brain Twin for a minimum of 4 weeks before the come to the randomization visit and the study medications are started. The duration of treatment is 12 weeks.",[29,28],[29,320,321,322,323],"CGRP","Onabotulinumtoxin A","CGRP monoclonal antibody","Combination of CGRP mAbs and onabotulinumtoxin A","2025-06-26",{"date":326,"type":42},"2025-06-27",{"date":328,"type":42},"2025-06-06",{"date":330,"type":22},"2029-04-30",{"name":332,"class":77},"Oslo University Hospital",6,{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":17,"minAge":340,"maxAge":341,"enrollmentInfo":342,"targetDuration":4,"studyType":62,"phases":344,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":50},"100581273","early-phase-1-study-of-the-effectiveness-and-safety-of-embolization-of-the-middle-meningeal-artery-using-non-adhesive-materials-squid-12-and-squid-18-in-the-treatment-of-patients-with-chronic-resistant-migraine-100581273","NCT06848166","Study of the Effectiveness and Safety of Embolization of the Middle Meningeal Artery Using Non-adhesive Materials SQUID 12 and SQUID 18 in the Treatment of Patients With Chronic Resistant Migraine","Inclusion Criteria:\n\n1. The patient has read, understood, signed, and dated the Patient Information Sheet with the informed consent form.\n2. The patient is aged between 35 and 59 years inclusive at the time of signing the Patient Information Sheet with the informed consent form.\n3. The diagnosis of \"chronic migraine\" according to the clinical guidelines on migraine by the Ministry of Health of the Russian Federation (2021) \u002F ICD-10 (2018), established at least 12 months before screening.\n4. Resistant nature of the migraine, determined by the doctor using the criteria of the European Headache Federation (EHF, 2020), established at least 6 months before screening.\n5. At least 14 days of headache during the screening period (28 days), of which 8 days of headache meet the definition of migraine (assessed based on the results of filling out the Headache Diary for 28 days during the screening period).\n6. Migraine, resistant to both pharmacological and non-pharmacological prevention and treatment methods, in the patient's history.\n7. Maximum level of headache during migraine days above 5 points (inclusive) on a 10-point numerical rating scale during the screening period.\n8. No positive effect on migraine symptoms (frequency and intensity of headache attacks) from previous botulinum toxin therapy (administration of OnabotulinumtoxinA, Relatox® (botulinum toxin type A - hemagglutinin complex 155 - 195 IU, administered every 12 weeks according to the PREEMPT protocol).\n9. Consent to use adequate contraceptive methods\\* and not serve as an egg\u002Fsperm donor from the time of signing the Patient Information Sheet with the informed consent form for participation in the study until the end of the study (for women with reproductive potential and men).\n\nExclusion Criteria:\n\n1. The patient has contraindications to undergoing embolization of the middle meningeal artery based on the medical history, results of examinations, and laboratory tests conducted during screening.\n2. Allergic reactions to contrast agents used during procedures before\u002Fduring the embolization procedure and associated procedures.\n3. The patient has a history of cerebral vascular malformations, arteriovenous malformations, brain aneurysms, brain tumors, hydrocephalus, arachnoiditis, cerebrospinal fluid circulation disorders, craniovertebral junction anomalies, platybasia, skull base deformities, severe traumatic brain injuries, stenosis, and occlusion of pre-cerebral arteries.\n4. The patient has a history of skull base fractures and consequences of skull base fractures, history of neurosurgical operations.\n5. A history of mental illness (including depression, confirmed by a psychiatrist during screening through the HADS questionnaire and Hamilton scale assessment), which, in the opinion of the psychiatrist, may affect the patient's ability to assess their condition, interfere with participation in the study, or impact the patient's safety during the study.\n6. A history of hyperthyroidism or diabetes. The presence of other endocrine disorders in the patient's history that, in the doctor's opinion, could interfere with participation in the study or affect the evaluation of efficacy and\u002For safety.\n7. History or data of drug addiction, alcoholism, or abuse of medications.\n8. Medication-induced headache at the time of screening and within 3 months (12 weeks) prior to screening.\n9. Other types of chronic headache in the patient's history within less than 12 months before screening, such as trigeminal autonomic cephalalgias (including cluster headaches, prolonged hemicrania), new daily persistent headaches, painful cranial neuropathies, retinal migraine, aura without headache, hemiplegic migraine, brainstem aura migraine, idiopathic intracranial hypertension without optic nerve edema, spontaneous intracranial hypertension, secondary headaches.\n10. The patient is unable to distinguish a migraine headache from other types of headache.\n11. The patient has migraine complications, such as status migrainosus, persistent aura without infarction, migraine infarction, migraine aura (as a trigger for epileptic seizures).\n12. Body mass index (BMI) below 18.5 or above 39.9 kg\u002Fm².\n13. The onset of migraine was diagnosed at an age older than 50 years.\n14. The presence of metabolic syndrome or cachexia.\n15. Severe cardiovascular diseases currently or in the past, including: chronic heart failure class III or IV (according to the New York Heart Association classification), clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), significant heart valve diseases, uncontrolled hypertension with systolic blood pressure \\> 180 mm Hg and diastolic blood pressure \\> 110 mm Hg, pulmonary embolism, or deep vein thrombosis.\n16. Varicose veins of the lower limbs, history of lower limb vein thrombosis.\n17. Ischemic heart disease, atherosclerosis of coronary vessels.\n18. Stenotic atherosclerosis of brachiocephalic arteries in the patient's history.\n19. Acute cerebrovascular accident or its consequences in the patient's history.\n20. The patient is pregnant or plans to become pregnant within the next 3 months.\n21. Atrial fibrillation, patent foramen ovale, anomalies of the interatrial septum, history of heart and coronary vessel surgeries.\n22. Signs of blood clotting disorders in the patient's history and screening, history of antiphospholipid syndrome.\n23. Use of anticoagulant drugs less than 5 days before the procedure.\n24. Uncontrolled bronchial asthma, severe chronic obstructive pulmonary disease in the patient's history.\n25. Renal insufficiency at screening based on the calculation of glomerular filtration rate (GFR) ≤ 60 mL\u002Fmin, based on serum creatinine levels at screening, or a history of renal insufficiency.\n26. History of liver insufficiency, elevated ALT and AST levels at screening.\n27. History of generalized pain syndrome, fibromyalgia.\n28. For women: use of combined oral contraceptives with a history of thrombosis of any localization.\n29. History of epilepsy, epileptic syndrome, seizure disorders, neurological conditions other than the primary condition (migraine).\n30. Presence of antibodies to HIV, hepatitis C virus, hepatitis B surface antigen (HbsAg), antibodies to T. Pallidum, or a history of HIV infection, hepatitis B, hepatitis C, or syphilis, either in the medical history or based on the results of serological blood tests at screening.\n31. Malignant neoplasms within 5 years before screening, or current or suspected oncological disease.\n32. Other serious, unstable, decompensated, or clinically significant medical or psychological conditions that, in the opinion of the doctor, may interfere with the patient's participation in the study or affect the evaluation of efficacy and\u002For safety.\n33. Participation in other interventional clinical trials, including the study completion visit, within 30 days prior to the screening, or planning to participate in such studies during the current study. Participation in non-interventional registry or epidemiological studies is allowed.\n34. The patient is unable to read or write, unwilling or unable to comply with the study protocol procedures; any other conditions that, in the opinion of the doctor, may prevent participation in the study, adherence to procedures, or contradict the patient's interests, as well as affect the study results.\n35. Employees of the medical institution conducting the study or the sponsor company, their family members, or subjects in dependent relationships.","35 Years","59 Years",{"count":343,"type":22},30,[345],"EARLY_PHASE1","To evaluate the effectiveness and safety of middle meningeal artery (MMA) embolization using non-adhesive materials SQUID 12 and SQUID 18 as a treatment method for patients with chronic resistant migraine.",[28],"2025-02-21",{"date":350,"type":42},"2025-02-26",{"date":352,"type":42},"2024-10-25",{"date":354,"type":22},"2027-05",{"name":356,"class":77},"Vedanta University Clinic",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":86,"sex":17,"minAge":365,"maxAge":87,"enrollmentInfo":366,"targetDuration":368,"studyType":24,"phases":4,"briefSummary":369,"conditions":370,"keywords":376,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":50},"100567944","molecular-phenotyping-of-migraine-patients-according-to-sex-and-age-through-cgrp-quantification-100567944","NCT06674772","Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification","Fenotipado Molecular De Pacientes Con Migraña Según Edad Y Sexo a Través De La Cuantificación De CGRP En Saliva Para Realizar Medicina De Precisión: Estudio FAST","FAST","Inclusion Criteria:\n\n* Migraine patients according to ICHD-3 criteria\n* Healthy controls paired to patient age and sex, without headache and without first degree family history of headache.\n\nExclusion Criteria:\n\n* Presence of any major medical or neurological illness.\n* Presence of any salivary gland malfunction.\n* Abuse or dependence to tobacco, alcohol or any drug in the previous 12 months before the enrollment.\n* Active migraine preventive treatment.\n* Pregnant or breastfeeding female.","6 Years",{"count":367,"type":22},440,"1 Day","Patients will be asked to visit the study center 2 times, the first time for clinical assessment and a second time for sample collection. Healthy controls will only be asked to visit the study center for sample collection. A sample of blood and saliva will be collected in order to measure CGRP levels and DNA and hormone testing.",[371,29,372,373,374,262,28,67,375],"Headache (Migraine)","Migraine Headache","Migraine with Aura","Migraine Without Aura","Episodic Migraine Headache",[29,320,377],"saliva","2024-11-11",{"date":380,"type":42},"2024-11-13",{"date":382,"type":42},"2022-11-29",{"date":384,"type":22},"2025-05",{"name":280,"class":77},{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":393,"targetDuration":4,"studyType":62,"phases":395,"briefSummary":396,"conditions":397,"keywords":398,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":406,"leadSponsor":408,"locationsCount":50},"100568670","efficacy-of-nerve-block-versus-botox-in-chronic-migraine-management-100568670","NCT06684249","Efficacy of Nerve Block Versus Botox in Chronic Migraine Management","A Randomized Controlled Trial Comparing the Efficacy of Supratrochlear and Greater Occipital Nerve Blocks to Botulinum Toxin A in the Management of Chronic Migraine","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* Diagnosis of chronic migraine, defined as having headaches on 15 or more days per month for more than three months, with at least 8 of those days meeting criteria for migraine.\n* Ability to provide informed consent and comply with study requirements.\n* No changes in prophylactic migraine medications in the last 3 months.\n\nExclusion Criteria:\n\n* History of allergy or hypersensitivity to local anesthetics or Botulinum toxin.\n* Previous nerve block or Botox treatment within the last 6 months.\n* Significant comorbid psychiatric or neurological disorders that could interfere with study participation or evaluation.\n* Pregnancy or breastfeeding.\n* Contraindications to either treatment as per product labels.",{"count":394,"type":22},64,[64],"The goal of this clinical trial is to determine whether nerve block injections (specifically, supratrochlear and greater occipital nerve injections) are as effective as Botulinum toxin A (Botox) injections in treating chronic migraine in adults.\n\nThe main questions it aims to answer are:\n\n* Do nerve block injections reduce the number of monthly migraine days compared to baseline?\n* Are there any differences in the frequency of migraine-related symptoms between the nerve block and Botox treatment groups?\n* Which treatment leads to higher patient satisfaction and improved quality of life?\n\nParticipants in this study will:\n\n* Receive either nerve block injections or Botox injections every 12 weeks.\n* Visit the clinic once every month for follow-ups and assessments.\n* Maintain a headache diary to record the frequency and severity of their migraines and any adverse effects experienced.\n* Researchers will compare the outcomes of the two groups to determine if one treatment is superior in terms of efficacy and patient satisfaction.",[265,67],[29,265,399,400,401,33],"Nerve Block","Botulinum Toxin","Botox","2024-11-10",{"date":404,"type":42},"2024-11-12",{"date":402,"type":42},{"date":407,"type":22},"2025-07-10",{"name":409,"class":410},"Zagazig University","OTHER_GOV",{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":86,"sex":418,"minAge":18,"maxAge":419,"enrollmentInfo":420,"targetDuration":4,"studyType":62,"phases":422,"briefSummary":423,"conditions":424,"keywords":426,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":78},"100566249","relieving-chronic-pain-psychosomatic-mechanisms-and-psychological-interventions-in-fibromyalgia-and-chronic-headache-100566249","NCT06652724","Relieving Chronic Pain: Psychosomatic Mechanisms and Psychological Interventions in Fibromyalgia and Chronic Headache","FIBROMIG","Inclusion Criteria:\n\n* minimum age of 18 years;\n* at least 5 years of education;\n* FM diagnosis according to the criteria reported by Wolfe (2016) for the FM group;\n* CM diagnosis according to Olesen (2018) for the CM group;\n* medical certification for FM and CM diagnosis for FibroMig group.\n\nExclusion Criteria:\n\n* severe psychiatric disorders and\u002For cognitive impairment;\n* difficulty understanding\u002Fexpressing in Italian;\n* history of other disorders characterized by chronic pain for FM and CM;\n* history of other neurological disorders besides migraine for CM and FibroMig;\n* history of other rheumatological disorders besides fibromyalgia for FM and FibroMig;\n* For the healthy control group: no diagnosis of FM or CM; no severe psychiatric disorders\u002Fcognitive impairment; no or low levels of depression; no history of rheumatological and\u002For neurological disorders.","FEMALE","50 Years",{"count":421,"type":22},400,[64],"Pain is one of the most important manifestations of the disease state and significantly affects people\\'s quality of life. According to the International Association for the Study of Pain (IASP), pain is not only a sensory experience related to the activation of the somato-sensory nervous system, but also an emotional experience, resulting from the cortical and emotional processing of nociceptive signals. This means that perceived pain is the result of a complex interaction between physical sensations and emotional responses.\n\nPain is classified according to two main criteria: duration and pathophysiological mechanism. In terms of duration, pain can be transient, acute, chronic, or persistent. In terms of pathophysiology, pain can be nociceptive, inflammatory, neuropathic, or nociplastic. The latter, in particular, is characterized by altered nociceptive function, without obvious peripheral damage, and is seen in conditions such as fibromyalgia and chronic migraine.\n\nChronic pain affects a significant proportion of the population, with estimated prevalence rates between 11% and 40%. According to the US Centers for Disease Control and Prevention, about 20.4 percent of adults suffer from chronic pain. This type of pain is more common in women, people of advanced age, and people with low socioeconomic status. In addition to its physical effects, chronic pain has a major psychological impact, increasing the risk of depression, anxiety, and social isolation. Socially and economically, the costs associated with the treatment and management of chronic pain are high.\n\nNociplastic pain (DN) refers to a chronic pain state that is not related to visible tissue damage or overt neuropathy, but in which there are alterations in the function of pain sensory pathways. The concept of central sensitization (CS), introduced in the 1990s, describes the amplification of pain signals at the level of the central nervous system, leading to increased sensitivity to pain (hyperalgesia) or pain in response to normally non-painful stimuli (allodynia). This central sensitization has been observed in conditions such as fibromyalgia and chronic migraine.\n\nFibromyalgia (FM) is a syndrome characterized by widespread musculoskeletal pain associated with fatigue, sleep disturbances, and cognitive deficits. The prevalence of FM is higher among women and tends to be associated with a high level of psychological distress, with anxiety symptoms and depression very common among patients. Although the precise cause of fibromyalgia is still unclear, studies suggest that central sensitization plays a central role in its etiology. Patients with fibromyalgia also have high levels of alexithymia, or the difficulty of identifying and describing emotions, and personality disorders such as avoidant or obsessive-compulsive.\n\nMigraine (CM) affects about 15 percent of the world\\'s population and is characterized by severe headache attacks, often associated with nausea, vomiting, and hypersensitivity to light and sound. Chronic migraine occurs when symptoms occur for at least 15 days per month. Several genetic and environmental factors contribute to the development of migraine, and there is growing evidence indicating a bidirectional relationship between migraine and depression. Anxiety and depression are also risk factors for migraine chronification.\n\nThe comorbidity between fibromyalgia and chronic migraine has been the subject of numerous studies. About 45%-80% of patients with fibromyalgia also have migraine, while 20%-36% of patients with migraine also have fibromyalgia. This high incidence of comorbidity suggests that there are common pathophysiological mechanisms between the two conditions, probably related to central sensitization and alterations in nociceptive pain pathways. Recent studies have confirmed that patients with both conditions (FibroMig) may have specific psychological and neurofunctional patterns that distinguish them from those with only one of the two diseases.\n\nThis study aims to explore the differences between people with fibromyalgia and chronic migraine, with the goal of identifying distinctive psychological and neurofunctional patterns that could help improve treatments for chronic pain management. An innovative aspect of the project is the identification of the FibroMig sub-population, namely those who suffer from both conditions. These patients might exhibit unique neurophysiological and psychological mechanisms that could be used to develop more targeted treatment strategies.",[425,28],"Fibromyalgia (FM)",[427,428,429,430,431,432,433],"fibromyalgia","chronic migraine","fmri","psychology","chronic pain","functional magnetic resonance","psychotherapy","2024-10-21",{"date":436,"type":42},"2024-10-22",{"date":438,"type":42},"2024-09-17",{"date":440,"type":22},"2025-09-30",{"name":442,"class":77},"University of Roma La Sapienza",{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":17,"minAge":451,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":62,"phases":453,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":465},"100493066","study-using-the-shiratronics-migraine-therapy-system-100493066","NCT05700318","Study Using the ShiraTronics Migraine Therapy System","A Pilot Study Assessing Preliminary Safety and Efficacy of The ShiraTronics Migraine Therapy System in Relieving, Interrupting, and Preventing Chronic Migraine","RELIEV-CM","Inclusion Criteria:\n\n1. Participants who are 22 years of age or older.\n2. History of migraine ≥ 12 months.\n3. Participants experiencing between 15 to 26 headache days per month, with at least 8 headache days (per month) with migraine phenotype presentation.\n4. Inadequate response to, unwilling, or contraindicated to Onabotulinumtoxin A and CGRP monoclonal antibodies therapy.\n5. Stable use of migraine medication.\n\nExclusion Criteria:\n\n1. Post-traumatic headache.\n2. Medication overuse headache.\n3. New daily persistent headache.\n4. Report experiencing unremitting, continuous headaches with no relief.\n5. Previously implanted neurostimulator to treat headache.\n6. History of cervical radiofrequency ablation or had any other intervention\u002Fdevice for migraine.","22 Years",{"count":290,"type":22},[64],"The purpose of this pilot study is to assess the preliminary safety and efficacy of the ShiraTronics Migraine Therapy System in prophylactic treatment of patients with refractory chronic migraine.",[67],"2024-07-14",{"date":458,"type":42},"2024-07-16",{"date":460,"type":42},"2023-05-05",{"date":462,"type":22},"2025-03",{"name":464,"class":49},"ShiraTronics",4,{"id":467,"slug":468,"hasResults":11,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":62,"phases":475,"briefSummary":476,"conditions":477,"keywords":478,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":50},"100542388","chronic-migraines-and-neurofdeeback-mindfulness-100542388","NCT06342219","Chronic Migraines and Neurofdeeback Mindfulness","Study Protocol for a Randomized Controlled Trial of Neurofeedback Mindfulness in Chronic Migraines","Inclusion Criteria:\n\n* have a diagnosis of chronic migraine from a clinician or have met the criteria for a chronic migraine diagnosis based on ICHD-3\n* reside in Saskatoon area\n* have a smartphone and internet connection for accessing the MUSE app\n* have no frequent background experience of meditation\n\nExclusion Criteria:\n\n* Comorbidity of Raynaud's syndrome or diabetes\n* Current use of a preventative migraine treatment over 6 months",{"count":474,"type":22},135,[64],"As the second phase of our study on migraine headaches and neurofeedback mindfulness, we will explore how chronic migraineurs will benefit from a long term practice (8 weeks) of neurofeedback mindfulness compared to a similar attention group and a waitlisted group. This randomized controlled trial will also explore if migrianuers could decrease their dependence on medicine intake after completion of the study.",[67],[479,480,481,482,483],"neurofeedback mindfulness","headache management self-efficacy","chronic migraines","dependence behaviours","migraine severity","2024-03-26",{"date":486,"type":42},"2024-04-02",{"date":488,"type":22},"2024-12",{"date":490,"type":22},"2026-06",{"name":492,"class":77},"University of Saskatchewan"]